Demis Hassabis: AI solved a 50-year biology challenge in just one year, saving a billion years of PhD research time.
“I think we'll be able to get down drug discovery from years to maybe months.”
“We managed to actually fold, using AlphaFold, in one year, all those 200 million proteins known to science.”
“So that's a billion years of PhD time saved.”
“We can expect to see some pretty dramatic health medicine breakthroughs in the coming few years.”
Restoring mitochondria–lysosome communication could open new therapeutic avenues in mitochondrial diseases, lysosomal storage disorders (Niemann-Pick C, mucolipidosis IV), neurodegeneration (Parkinson’s, Charcot-Marie-Tooth type 2), cardiovascular disease, and aging.
A new review in EMBO Molecular Medicine (Callender, Afroz & Raimundo, 2026) shows that mitochondria and lysosomes form a dynamic, bidirectional network via membrane contact sites, ion exchange (Ca²⁺, Fe²⁺), lipid/cholesterol transfer, and mitochondria-derived vesicles — far beyond classical mitophagy.
Disrupting this crosstalk is a shared feature across these conditions. The key insight: targeting the communication network itself, rather than either organelle in isolation, may better restore cellular homeostasis.
→ https://t.co/R1vnJTd02C
#Mitochondria #Lysosomes #Neurodegeneration #Aging #RareDisease #OrganelleCrosstalk #CellBiology
Yesterday on X: Mitochondria proved decisive in two new disease mechanisms: they act as the redox-sensitive gatekeepers of hepatic fat oxidation in MASLD, and they serve as the primary site where novel compounds can ignite lipid peroxidation to kill cancer cells.
• Nature Communications: Mitochondria control hepatic lipid catabolism through the ROMO1–LONP1–SIRT3 axis. ROMO1 protects LONP1 from oxidation; when ROMO1 is lost, oxidized LONP1 degrades SIRT3, causing mitochondrial protein hyperacetylation, impaired fatty-acid oxidation and steatosis. Restoring ROMO1 or SIRT3 reverses the lipid accumulation.
→ https://t.co/QWluGFG6Pi
• Cell: Mitochondria are the entry point for a new ferroptosis strategy. Tetraoxanes (WMK-1/2) accumulate in mitochondria, are activated by labile Fe²⁺, and generate radicals that initiate phospholipid peroxidation locally. This triggers mitochondrial damage and ferroptosis, suppresses tumors (including some GPX4-inhibitor-resistant models), and can enhance anti-PD-1 responses.
→ https://t.co/lMzzKDEhid
• Additional circulating notes: Near-infrared light continues to be discussed for its ability to stimulate cytochrome c oxidase and support mitochondrial ATP and melatonin production; progesterone synthesis depends on mitochondrial cholesterol conversion in the corpus luteum.
#Mitochondria #MASLD #Ferroptosis #Cancer #Metabolism #Redox #Science #Longevity
🧬🔥 What if fatty liver disease is driven not only by excessive lipid synthesis, but by oxidative activation of a mitochondrial protease that destroys a key regulator of fat oxidation?
A new study in Nature Communications identifies a ROMO1–LONP1–SIRT3 redox signaling axis that controls hepatic fatty acid catabolism and protects against metabolic dysfunction-associated steatotic liver disease (MASLD/MASH).
The central discovery:
ROMO1 deficiency → LONP1 cysteine oxidation → SIRT3 degradation → Mitochondrial protein hyperacetylation → Impaired fatty acid oxidation → Hepatic steatosis
Restoring ROMO1 or SIRT3 protected against liver lipid accumulation in mouse models, while aged rhesus macaques with spontaneous fatty liver exhibited reduced ROMO1 and SIRT3 expression.
🔬 1. ROMO1 protects hepatic lipid homeostasis
ROMO1 is a small mitochondrial inner-membrane protein recently identified as a protector of mitochondrial protein thiols.
Researchers generated hepatocyte-specific mouse models:
• hKO: ROMO1 knockout, approximately 90% depletion.
• hOE: ROMO1 overexpression, approximately 1.1-fold increase in protein abundance.
Even under standard chow feeding, ROMO1-deficient mice developed:
• Increased hepatic triglycerides and cholesterol.
• Greater lipid droplet accumulation.
• Elevated histological steatosis scores.
• Moderately increased serum AST and ALT.
Importantly, these changes occurred without major differences in body weight or body composition.
Re-expression of ROMO1 reversed lipid accumulation in deficient hepatocytes.
ROMO1 is therefore required for normal hepatic lipid metabolic homeostasis.
⚡ 2. The primary defect is impaired mitochondrial fatty acid oxidation
The investigators tested whether ROMO1 altered lipid uptake, synthesis, or degradation.
Fluorescent fatty acid uptake was comparable between control and genetically modified hepatocytes.
Protein abundance of major lipogenesis-associated enzymes—including ACC1, FASN, SREBP1, DGAT1, and DGAT2—was largely unchanged.
However, Seahorse analysis of isolated liver mitochondria using palmitoylcarnitine revealed:
ROMO1 knockout:
• ATP-linked oxygen consumption ↓
• Maximal mitochondrial respiration ↓
ROMO1 overexpression:
• ATP-linked oxygen consumption ↑
• Maximal mitochondrial respiration ↑
These findings identify mitochondrial fatty acid oxidative capacity as a major process regulated by ROMO1.
🧬 3. ROMO1 deficiency causes SIRT3 protein depletion
Quantitative mitochondrial proteomics identified SIRT3 as a prominent protein reduced following ROMO1 deletion.
SIRT3 protein abundance decreased by approximately 55%.
SIRT3 is the principal mitochondrial NAD⁺-dependent deacetylase regulating numerous metabolic enzymes.
Its depletion was accompanied by widespread mitochondrial protein hyperacetylation.
Affected pathways included:
• Fatty acid β-oxidation.
• Tricarboxylic acid cycle.
• Oxidative phosphorylation.
Notably, mitochondrial NAD⁺, NADH, and related metabolite measurements were largely unchanged.
Thus, increased acetylation was primarily associated with SIRT3 protein loss, rather than an obvious depletion of its metabolic cofactors.
🔋 4. Restoring SIRT3 rescues fatty liver phenotypes
The researchers reintroduced SIRT3 into ROMO1-deficient hepatocytes.
This normalized intracellular lipid accumulation.
In ROMO1-deficient mice, hepatocyte-directed SIRT3 expression reduced:
• Hepatic steatosis.
• Liver triglycerides and cholesterol.
• Histological disease activity.
• Serum AST and ALT.
These rescue experiments establish SIRT3 depletion as a major mediator of ROMO1-associated hepatic lipid accumulation.
🧪 5. LONP1 directly degrades SIRT3
The investigators screened five major mitochondrial proteases:
• LONP1
• CLPP
• SPG7
• AFG3L2
• YME1L1
Only LONP1 depletion substantially restored SIRT3 protein abundance.
Additional experiments demonstrated:
• Physical association between LONP1 and SIRT3.
• ATP-dependent SIRT3 degradation by purified recombinant LONP1.
• Increased SIRT3 abundance following pharmacological LONP1 inhibition.
• Rescue of lipid accumulation following LONP1 depletion.
Importantly, Sirt3 mRNA levels were not significantly altered by ROMO1 deletion.
The mechanism is post-translational: LONP1 regulates SIRT3 protein stability.
🔥 6. Oxidation activates LONP1-mediated SIRT3 degradation
The investigators next asked how ROMO1 controls LONP1 activity.
LONP1 protein abundance remained largely unchanged after ROMO1 manipulation.
Instead, its oxidation state changed.
ROMO1 deficiency increased oxidation of multiple LONP1 cysteine residues.
Experiments using oxidants and reductants demonstrated:
Oxidative conditions → LONP1-mediated SIRT3 degradation ↑
Reducing conditions → LONP1-mediated SIRT3 degradation ↓
N-acetylcysteine restored SIRT3 abundance and reduced lipid accumulation in ROMO1-deficient hepatocytes.
Conversely, mitochondria-targeted paraquat reduced SIRT3 abundance and induced lipid accumulation in control cells.
ROMO1 overexpression protected against these effects.
These findings establish redox-sensitive regulation of LONP1 proteolysis.
🧠 7. LONP1 C626 and C693 are critical redox-sensitive residues
A major mechanistic advance was the identification of cysteine residues controlling oxidation-dependent LONP1 activity.
Mass spectrometry detected sulfenylation at:
• C509
• C626
• C671
• C898
Functional mutagenesis identified C626 and C693 as particularly important for oxidation-induced SIRT3 degradation.
The C626S/C693S double mutant exhibited substantially attenuated oxidation-dependent proteolytic activation.
Structural modeling placed these residues near ATPase regulatory motifs:
C626 → Walker B motif, approximately 5.9 Å
C693 → Sensor 2 motif, approximately 7.6 Å
This suggests that cysteine oxidation may influence ATPase-associated conformational or catalytic regulation.
An important distinction: C693 sulfenylation was not directly detected by mass spectrometry, although mutation experiments established its functional importance.
🩺 8. ROMO1 protects against steatotic liver injury across three dietary models
The investigators tested three independent metabolic stress models:
Choline-deficient high-fat diet (CDHFD)
ROMO1 deficiency exacerbated steatosis and liver injury.
ROMO1 overexpression substantially reduced lipid accumulation and liver damage.
GAN-DIO model
ROMO1 deletion aggravated metabolic stress-associated hepatic pathology.
ROMO1 overexpression improved liver outcomes.
FAT-MASH model
ROMO1 deficiency increased:
• Hepatic steatosis.
• Fibrotic area.
• Liver triglycerides and cholesterol.
• Serum AST and ALT.
Conversely, ROMO1 overexpression significantly alleviated these abnormalities.
Across models, liver injury was associated with increased LONP1 sulfenylation and reduced SIRT3 abundance.
These experiments support the protective role of the ROMO1–LONP1–SIRT3 axis during metabolic stress.
🐒 9. Aged rhesus macaques provide translational evidence
The investigators examined liver samples from aged rhesus macaques:
Five controls versus five animals with spontaneous hepatic steatosis.
Steatotic livers exhibited:
• Reduced ROMO1 protein.
• Approximately 60% lower SIRT3 protein.
• Increased protein oxidation.
• Unchanged LONP1 protein abundance.
• Reduced ROMO1 mRNA.
• No significant change in SIRT3 or LONP1 mRNA.
ROMO1 and SIRT3 protein abundances were positively correlated.
R² = 0.66; p = 0.0045
These findings suggest that the pathway may be relevant beyond experimentally induced mouse steatosis.
However, LONP1 sulfenylation could not be directly measured in the macaque samples.
🎯 10. A new model of redox-controlled hepatic lipid metabolism
Healthy mitochondrial state
ROMO1 preserves mitochondrial protein thiols
↓
LONP1 oxidation is restrained
↓
SIRT3 protein stability maintained
↓
Mitochondrial metabolic enzymes deacetylated
↓
Fatty acid oxidation maintained
↓
Hepatic lipid accumulation limited
ROMO1-deficient or oxidatively stressed state
ROMO1 protection ↓
↓
LONP1 sulfenylation ↑
↓
LONP1-mediated SIRT3 degradation ↑
↓
SIRT3 abundance ↓
↓
Mitochondrial protein acetylation ↑
↓
Fatty acid oxidation ↓
↓
Hepatic steatosis and metabolic injury ↑
The key insight is that oxidative stress can impair lipid metabolism by altering mitochondrial protein turnover—not merely through direct oxidative damage to metabolic enzymes.
💊 11. Therapeutic implications for MASLD/MASH
The findings suggest several possible therapeutic strategies.
ROMO1 restoration
Increasing hepatocyte ROMO1 activity may preserve mitochondrial protein redox homeostasis.
Selective LONP1 redox modulation
Preventing excessive oxidation-dependent LONP1 activity could stabilize SIRT3.
SIRT3 stabilization
Preserving endogenous SIRT3 protein may maintain mitochondrial fatty acid oxidation without requiring increased Sirt3 transcription.
Mitochondrial redox protection
Targeted interventions could potentially prevent pathological protease activation.
However, LONP1 is essential for mitochondrial protein quality control. Broad inhibition could disrupt normal proteostasis.
Therefore, selective modulation of pathological redox activation may be preferable to complete protease inhibition.
These remain therapeutic hypotheses, not clinically validated interventions.
🚨 12. Critical limitations
• The principal causal experiments were performed in mice and cultured cells.
• No human MASLD/MASH liver cohort was examined.
• The rhesus macaque cohort included only ten animals.
• LONP1 sulfenylation was not directly measured in macaque liver.
• C693 sulfenylation was not directly identified by mass spectrometry.
• The precise structural mechanism connecting cysteine oxidation to LONP1 catalytic activity remains unresolved.
• The contribution of other LONP1 substrates was not comprehensively assessed.
• Whether the pathway regulates hepatic glucose and amino acid metabolism remains unknown.
• Mitochondrial respiration assays assessed oxidative capacity rather than directly measuring whole-organism fatty acid flux.
• No selective therapeutic ROMO1 activator or redox-specific LONP1 modulator was evaluated.
• Long-term safety of increasing ROMO1 or modifying LONP1 activity remains uncertain.
💡 Key takeaway
Mitochondrial redox balance controls hepatic fat metabolism partly by determining the stability of SIRT3.
This study establishes ROMO1 as a protector of LONP1 cysteine redox status, preventing excessive LONP1-mediated SIRT3 degradation.
By preserving SIRT3-dependent mitochondrial protein deacetylation, ROMO1 supports fatty acid oxidation and limits hepatic lipid accumulation.
The broader conceptual advance is a previously underappreciated connection:
Mitochondrial redox regulation ↔ Protease activity ↔ Protein stability ↔ Metabolic enzyme acetylation ↔ Lipid catabolism
This pathway provides a promising mechanistic foundation for investigating therapies targeting mitochondrial proteostasis in MASLD/MASH.
📄 Peng K, Qiu S, Ren Y, et al.
A redox-coupled ROMO1–LONP1–SIRT3 axis controls hepatic lipid catabolism.
Nature Communications (2026). Article in Press.
DOI: https://t.co/VUY5qKcVYP
Proteomics datasets: PXD081689, PXD081692, PXD081729
Research institution: Peking University, Beijing, China.
#MASLD #MASH #FattyLiver #ROMO1 #LONP1 #SIRT3 #Mitochondria #RedoxBiology #FattyAcidOxidation #Proteostasis #Sulfenylation #MetabolicDisease #LiverMetabolism #NatureCommunications
Yesterday on X: Key mitochondrial science highlights
Mitochondria emerged as both a vulnerable target and an active driver of pathology: their respiratory failure defines a skeletal-muscle metabolic myopathy in HFpEF, their iron overload explains cysteine toxicity, and targeted mitochondrial support can rejuvenate aging oocytes.
• Circulation: Heart Failure: In a rat model of cardiometabolic HFpEF, mitochondria in skeletal muscle show clear respiratory dysfunction (reduced complex I/II activity, downregulated OXPHOS and TCA programs). This is accompanied by incomplete fatty-acid oxidation, impaired BCAA catabolism and phospholipid remodeling, creating an acquired metabolic myopathy that contributes to exercise intolerance beyond the heart itself.
→
• Aging Cell: The mitochondria-targeted peptide elamipretide (SS-31) improves oocyte quality and fertility in aged mice by enhancing mitochondrial metabolism, organelle reorganization and cytoskeletal dynamics. It also boosts maturation, fertilization and cleavage rates of aged human oocytes in vitro, acting in part via the vitamin B6–VEGF axis.
→ https://t.co/sVpgntREHL
• Nature Metabolism: Excess free cysteine is toxic because it mobilizes iron from ferritin and drives its accumulation inside mitochondria. The resulting iron overload damages iron–sulfur cluster proteins and impairs respiration, defining a distinct mitochondrial iron-dependent cell death that can be prevented by blocking mitochondrial iron import.
→ https://t.co/eBLcQeWuyl
• Broader perspective circulating: Mitochondria act as master regulators linking metabolism to aging, SASP, immunity and biological clocks (via TIM23 import defects releasing mtDNA, citrate export acetylating histones, and mitoAMPK controlling mitophagy).
→ https://t.co/Kay3qA7pT8
#Mitochondria #HFpEF #Aging #Fertility #IronMetabolism #Metabolism #Longevity
🧬🔥 What if exercise intolerance in HFpEF is not simply a consequence of cardiac dysfunction—but also reflects an acquired skeletal muscle metabolic myopathy?
A new multiomics study in Circulation: Heart Failure reveals extensive metabolic remodeling in skeletal muscle from a rat model of cardiometabolic heart failure with preserved ejection fraction (HFpEF).
The central finding:
Mitochondrial respiratory dysfunction + Incomplete fatty acid oxidation + Impaired BCAA catabolism + Tryptophan metabolic remodeling + Phospholipid disruption
Together, these abnormalities define a skeletal muscle phenotype consistent with metabolic myopathy.
🔬 1. Integrated multiomics reveals widespread skeletal muscle dysfunction
Researchers studied 26-week-old male rats:
• ZSF1 obese rats with cardiometabolic HFpEF: n = 8
• Wistar Kyoto lean controls: n = 8
Gastrocnemius muscle underwent:
• Bulk RNA sequencing
• Quantitative proteomics
• Metabolomics
• Lipidomics
Additional targeted analyses examined plasma, oxidative soleus muscle, and predominantly glycolytic extensor digitorum longus (EDL) muscle.
The HFpEF rats exhibited reduced exercise capacity, impaired grip strength, smaller muscle fibers, increased interstitial and perivascular fibrosis, reduced capillary density, and adipocyte infiltration.
Importantly, intramuscular adipose infiltration (myosteatosis) was distinguished from lipid storage within individual muscle fibers.
🧬 2. Mitochondrial energy metabolism is profoundly altered
Transcriptomics identified 1,242 differentially expressed genes, including 646 downregulated and 596 upregulated genes.
Proteomics detected 1,765 proteins, of which 334 were differentially expressed.
Key downregulated pathways included:
Oxidative phosphorylation: NES −2.13
Electron transport chain: NES −2.04
TCA cycle: NES −1.84
Conversely, the following pathways were enriched:
PPAR signaling: NES +2.27
Tryptophan metabolism: NES +1.85
Amino acid metabolism: NES +1.79
These findings indicate a shift away from coordinated mitochondrial energy production toward alternative metabolic and lipid-handling programs.
⚡ 3. Respiratory complex I and II dysfunction provides functional evidence
The investigators measured mitochondrial respiratory-chain enzyme activities in tibialis anterior muscle.
Both complex I and complex II activities were significantly reduced.
Approximately 40% of complex I assembly-associated genes were downregulated in gastrocnemius muscle.
Metabolomics also identified:
• Isocitrate accumulation
• Increased NADH
• Altered NADH/NAD⁺ balance
• Increased selected adenine nucleotides
• Elevated circulating aconitic acid and lactate
These findings are consistent with impaired mitochondrial electron transport and altered cellular redox balance.
However, metabolite accumulation alone cannot establish absolute TCA-cycle flux or ATP synthesis rates.
🔋 4. Glycolysis is transcriptionally suppressed despite metabolite accumulation
The study identified reductions in multiple glycolysis-associated proteins:
• Hexokinase (HK) ↓
• Aldolase A (ALDOA) ↓
• Phosphofructokinase (PFK) ↓
Enolase 1 (ENO1), however, increased.
At the metabolite level:
• Glucose ↑
• Glucose-6-phosphate ↑
• Fructose-6-phosphate ↑
This combination suggests that glycolytic intermediates accumulate despite reduced abundance of several enzymes involved in their downstream utilization.
The findings support impaired glucose metabolism rather than a simple global increase in glycolytic activity.
🧪 5. BCAA catabolism is impaired in skeletal muscle
Branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine—are important substrates for skeletal muscle metabolism.
Researchers found reduced expression of several BCAA-catabolic enzymes, including:
• BCAT2
• DBT
• MMUT
Meanwhile, BCAAs accumulated in:
• Gastrocnemius
• Soleus
• EDL
Circulating isoleucine and valine also increased.
A particularly informative finding involved C5-OH acylcarnitine, a metabolite associated with leucine catabolism.
C5-OH concentrations were reduced in plasma, soleus, and EDL muscle.
This combination of increased substrate abundance and reduced downstream catabolic products supports a defect in BCAA utilization.
🧠 6. Tryptophan metabolism shifts toward serotonin-associated pathways
The study identified substantial remodeling of the tryptophan–kynurenine pathway.
In gastrocnemius muscle:
TDO2 expression: +2.3-fold
Kynurenine: −0.88 log₂FC
Kynurenate: −0.67 log₂FC
Serotonin: +0.53 log₂FC
Expression of kynurenine aminotransferases, including KYAT1 and KYAT3, was reduced.
The kynurenine-to-tryptophan ratio, used as a proxy for pathway activity, also decreased in gastrocnemius and EDL muscle.
Interestingly, serotonin increased in EDL but decreased in soleus.
These findings indicate that tryptophan metabolism is remodeled differently across muscle fiber-type environments.
The authors propose that reduced kynurenine-associated metabolism may contribute to altered NAD⁺ homeostasis.
However, direct isotope-tracing evidence demonstrating reduced tryptophan-derived NAD⁺ synthesis was not provided.
🔥 7. Fatty acid oxidation machinery increases—but oxidation appears incomplete
One of the most striking findings was the apparent mismatch between fatty acid oxidation machinery and metabolic outcomes.
Several fatty acid oxidation-associated proteins increased:
• ACADL
• ACADM
• ACADS
• ACADSB
• ECH1
• ECI1
• ECI2
Fatty acid transport-associated proteins, including SLC25A20 and CrAT, also increased.
Yet the muscles accumulated substantial quantities of long-chain and very-long-chain acylcarnitines.
This suggests that fatty acid entry and initial oxidative processing may exceed the capacity for complete downstream oxidation.
Greater expression of β-oxidation machinery does not necessarily indicate more efficient fatty acid oxidation.
🧬 8. Hydroxyacylcarnitines reveal a potentially harmful lipid signature
Targeted lipidomics confirmed accumulation of long-chain hydroxyacylcarnitines in both soleus and EDL muscle.
These metabolites are relevant because similar species have been associated with mitochondrial myopathies and impaired fatty acid oxidation.
The investigators also observed accumulation of:
• Long-chain acylcarnitines
• Very-long-chain acylcarnitines
• Monoacylglycerols
• Diacylglycerols
Plasma free carnitine availability was reduced by approximately 45%.
Free carnitine was also depleted in oxidative soleus muscle.
The authors propose that excess fatty acid delivery increases demand for acyl-group buffering, potentially compromising carnitine and CoA homeostasis.
However, skeletal muscle CoA depletion and the precise direction of fatty acid oxidation flux were not directly established.
⚙️ 9. ECHDC2 emerges as a candidate metabolic regulatory node
ECHDC2 was reduced at both transcript and protein levels.
This enzyme is structurally related to proteins involved in maintaining acyl-CoA metabolic fidelity.
The investigators propose that reduced ECHDC2 may impair the handling of unusual acyl-CoA species and contribute to dysfunction in both fatty acid and BCAA metabolism.
This is a potentially important intersection between:
Lipid overload ↔ Acyl-CoA homeostasis ↔ BCAA metabolism
However, the study did not perform ECHDC2-specific genetic rescue or pharmacological intervention.
Its causal contribution remains hypothetical.
🧫 10. PLA2G7-associated phospholipid remodeling emerges as a novel signature
A major discovery involved the remodeling of skeletal muscle membrane phospholipids.
The investigators identified:
PLA2G7 expression ↑
GPCPD1 expression ↓
SLC44A2 protein abundance ↓
PLA2G7 was among 61 genes commonly upregulated across gastrocnemius, soleus, and EDL muscles.
Lipidomics identified increased abundance of several lysophospholipids, including lysophosphatidylcholine (LPC).
These changes occurred alongside altered choline metabolism.
The findings suggest that increased phospholipid hydrolysis and disrupted choline cycling may contribute to membrane remodeling and inflammatory signaling.
Importantly, PLA2G7 activity was not directly manipulated, so its role as a causal driver remains unproven.
🧬 11. Membrane lipid composition shifts toward potentially inflammatory species
Among detected phospholipids:
• 18 of 46 phosphatidylcholine species decreased.
• 10 of 46 phosphatidylcholine species increased.
• 16 of 23 phosphatidylethanolamine species increased.
• Multiple lysophospholipid species accumulated.
The study also identified remodeling of arachidonic acid- and DHA-containing phospholipids.
These changes were associated with:
ACSL4 ↑
ACSL6 ↓
The authors interpret the findings as consistent with altered omega-6/omega-3 phospholipid composition and potentially increased susceptibility to inflammatory lipid signaling.
However, membrane fluidity, receptor signaling, and excitation–contraction coupling were not directly established as consequences of these lipid changes.
🧪 12. Peroxisomal dysfunction may contribute to membrane instability
Peroxisomes participate in very-long-chain fatty acid metabolism and the synthesis of ether-linked phospholipids.
The investigators observed:
• Reduced plasmalogen abundance
• Reduced ether-linked phosphatidylcholine species in skeletal muscle
• Accumulation of selected very-long-chain lipid intermediates
• Evidence consistent with altered peroxisomal lipid processing
Plasmalogens are important membrane components and may contribute to protection against oxidative lipid damage.
The combination of plasmalogen depletion and altered acylcarnitine profiles supports a model of coordinated mitochondrial–peroxisomal metabolic dysfunction.
However, direct peroxisomal β-oxidation flux and organelle-specific enzymatic capacity were not comprehensively measured.
🩸 13. Choline and TMAO metabolism are altered systemically
The investigators also identified changes in circulating metabolites associated with phospholipid turnover.
Plasma choline ↑
Plasma TMAO ↑
Plasma trigonelline ↓
Tissue-specific differences were observed:
• Choline increased in EDL.
• TMAO increased in soleus.
• Trigonelline decreased in both muscles.
Because TMAO is generated primarily through gut microbial and hepatic metabolic processes, its accumulation in muscle may reflect systemic metabolic dysfunction.
The findings suggest that circulating metabolites could potentially provide information about peripheral tissue pathology.
However, their diagnostic performance as HFpEF biomarkers was not established.
🎯 14. An integrated model of skeletal muscle metabolic myopathy
The proposed disease framework is:
Cardiometabolic HFpEF
↓
Obesity-associated lipid overload + Insulin resistance
↓
Increased fatty acid transport and PPAR signaling
↓
Mitochondrial and peroxisomal metabolic stress
This produces several interconnected abnormalities:
Mitochondria
Complex I/II activity ↓
OXPHOS-associated programs ↓
TCA-cycle dysregulation
Incomplete β-oxidation
Amino acid metabolism
BCAA catabolism ↓
BCAA accumulation ↑
Tryptophan–kynurenine pathway remodeling
Lipid metabolism
Long-chain acylcarnitines ↑
Hydroxyacylcarnitines ↑
Plasmalogens ↓
PLA2G7-associated phospholipid remodeling
Muscle pathology
Myosteatosis ↑
Fibrosis ↑
Capillary density ↓
Muscle fiber size ↓
Together, these changes provide a molecular framework potentially explaining reduced muscle quality and exercise capacity in cardiometabolic HFpEF.
Importantly, the study establishes coordinated associations rather than proving every causal connection in this model.
🩺 15. Implications for HFpEF treatment
The findings support considering skeletal muscle as a therapeutic target alongside the heart.
Potential research directions include:
Mitochondrial restoration
Improving respiratory-chain function and oxidative metabolic efficiency.
BCAA metabolic correction
Restoring amino acid catabolism and reducing substrate accumulation.
Lipid-overload reduction
Limiting excessive fatty acid delivery and incomplete oxidation.
Peroxisomal protection
Preserving ether-lipid synthesis and plasmalogen homeostasis.
PLA2G7-associated phospholipid remodeling
Investigating whether modifying phospholipid hydrolysis improves muscle function.
Exercise-based metabolic rehabilitation
Determining whether targeted exercise interventions reverse the identified molecular abnormalities.
These are mechanistic and therapeutic hypotheses. No intervention in this study demonstrated reversal of the metabolic myopathy.
🚨 16. Critical limitations
• Integrated multiomics was performed primarily in male rats.
• The principal HFpEF and control groups included eight animals each.
• The ZSF1 obese model captures important cardiometabolic HFpEF features but does not reproduce all human disease phenotypes.
• Bulk tissue measurements cannot distinguish myofiber-intrinsic changes from those arising in adipocytes, fibroblasts, endothelial cells, or immune cells.
• Metabolomics provides steady-state metabolite abundance rather than direct metabolic flux.
• No isotope-tracing experiments quantified fatty acid, BCAA, or tryptophan pathway flux.
• The study did not establish whether PLA2G7, ECHDC2, or altered phospholipids causally impair muscle function.
• The proposed effects on membrane mechanics and excitation–contraction coupling were not directly demonstrated.
• The contribution of skeletal muscle dysfunction to exercise intolerance was not experimentally isolated from cardiac, vascular, renal, and adipose tissue abnormalities.
• Direct validation in human cardiometabolic HFpEF skeletal muscle remains necessary.
💡 Key takeaway
HFpEF-associated exercise intolerance may reflect a systemic metabolic disorder in which skeletal muscle develops its own pathological metabolic phenotype.
This study integrates transcriptomics, proteomics, metabolomics, and lipidomics to identify coordinated defects in mitochondrial energy metabolism, amino acid catabolism, fatty acid oxidation, and membrane phospholipid homeostasis.
Its most important conceptual advance is the recognition that skeletal muscle abnormalities in cardiometabolic HFpEF resemble an acquired metabolic myopathy, rather than merely a secondary consequence of impaired cardiac function.
The findings provide a roadmap for future studies investigating muscle-directed interventions to improve exercise capacity, physical function, and frailty in HFpEF.
📄 Allerton TD, Arabie D, Malone K, et al.
Multiomics Integration Reveals a Skeletal Muscle Metabolic Myopathy in Cardiometabolic HFpEF.
Circulation: Heart Failure (2026)
Volume 19, e014126.
DOI: https://t.co/ym3dOKPrqb
RNA-seq: GEO GSE347054
Data and analysis code:
https://t.co/UGcWJhMdtt
https://t.co/4fTuV4mdMJ
#HFpEF #HeartFailure #SkeletalMuscle #MetabolicMyopathy #Mitochondria #MitochondrialDysfunction #BCAA #TryptophanMetabolism #FattyAcidOxidation #Acylcarnitines #PLA2G7 #Peroxisomes #Myosteatosis #Sarcopenia #Multiomics #CardiometabolicHealth
Mitochondrial dysfunction is the crux. As highlighted in this post by @heniek_htw
circadian disruption of mitochondria connects to neurodegeneration, psychiatric disorders, cancer, and cardiometabolic diseases—via clock gene alterations, melatonin/cortisol rhythmicity, light cycle changes, sleep deprivation, and feeding timing.
What if your mitochondria ran on a 24-hour clock?
Circadian system drives their daily shape & metabolism, but meal timing can reset them. Melatonin links ancient redox cycles to this clock. Disruption is tied to neurodegeneration, diabetes & cancer.
https://t.co/6A37VRGyOb
Yesterday on X: Key mitochondrial science highlights
Mitochondria took center stage in several discussions, showing up as timekeepers shaped by circadian rhythms and melatonin, as transferable organelles that help resolve pain, and as integrity-dependent targets that influence how cancer cells evade immune killing.
• Circadian control of mitochondria: The circadian system regulates daily changes in mitochondrial shape and metabolism. Meal timing can reset these rhythms, and melatonin helps link ancient redox cycles to the clock. Disruption is associated with neurodegeneration, diabetes, and cancer.
→ https://t.co/HYV07GJydN
• Mitochondrial transfer in pain resolution: Macrophages can physically transfer mitochondria into sensory neurons during recovery from inflammatory pain. Blocking this transfer impairs normal pain resolution, indicating that mitochondria supplied by immune cells help restore respiratory capacity in neighboring neurons (referencing a 2022 Neuron study).
→ (discussed in detail by @jack3daniels)
• Cancer Immunology Research (online Nov 12): The miRNA core machinery (AGO2/ANKRD52) maintains mitochondrial integrity in tumor cells. Loss of this machinery collapses mitochondrial membrane potential, lowers ATP, fragments mitochondria, and makes cancer cells far more sensitive to NK-cell killing by releasing repression of pro-apoptotic factors.
→ https://t.co/BEPqe5KwiQ
• Additional notes circulating: Metformin’s inhibition of mitochondrial complex I blunts exercise-induced gains in mitochondrial respiration and muscle mass in older adults. Near-infrared light and mitochondrial melatonin production were also highlighted as potential ways to support mitochondrial antioxidant defense.
#Mitochondria #Longevity #Metabolism #Science #Health #Aging #Biohacking #CircadianRhythm
This Motor Keeps You Alive
- Inside nearly every cell in your body, a microscopic motor called ATP synthase spins over 100 times per second, converting proton flow into ATP—the energy that powers your cells. Trillions of these tiny molecular machines work continuously to keep you alive.
Yesterday on X: Key mitochondrial science highlights
New work clarifying how mitochondria actively drive or limit disease processes: they enable flexible thermogenesis in brown fat, become dangerously hyperactive when ATM is missing in fatty liver, lose functional OXPHOS isoforms after kidney injury, and can be transferred between cells in the nervous system.
• Nature Metabolism: Mitochondria in brown adipose tissue sustain heat production (via UCP1 uncoupling) even when glucose uptake is almost abolished. GLUT4-dependent glucose use supports optimal thermogenesis only under low-fat conditions; with more dietary fat, mitochondria switch fuels and keep generating heat.
→ https://t.co/zC7snholmA
• EMBO Molecular Medicine: In MASLD, mitochondria become hyperactive when ATM is absent in hepatocytes. This excessive respiration + proton leak depletes energy and nucleotides, increases ROS and lipotoxicity, and worsens fibrosis — showing that too much mitochondrial activity can be as damaging as too little.
→ https://t.co/bWKpIFwTkw
• bioRxiv preprint: After acute kidney injury, mitochondria-related OXPHOS genes don’t just decrease in expression; their protein-coding isoforms are preferentially lost. This isoform-level change may further impair mitochondrial respiratory capacity in injured proximal tubules.
→ (detailed thread by @changmyung1981; preprint posted ~Nov 11–13 2026)
• Molecular Biology of the Cell: Mitochondrial respiratory state directly modulates α-synuclein toxicity. Both elevated respiration and respiratory dysfunction make yeast cells more vulnerable to this Parkinson’s-associated protein, linking mitochondrial bioenergetics to proteotoxic stress.
→ https://t.co/0ztT3xLrd7
• Review on the nervous system: Mitochondria themselves can be released or transferred between cells (via extracellular vesicles, free mitochondria, or tunnelling nanotubes). This exchange may support repair, signalling, or targeted degradation in brain health and disease.
→ https://t.co/h9rmNfoW6N
#Mitochondria #MitoScience #BAT #MASLD #KidneyInjury #OXPHOS #MetabolicFlexibility #CellBiology
Yesterday on X: Key mitochondrial science highlights
A solid day for mitochondrial research on X, with new work on the mitochondrial epigenome in brain aging, neuronal vulnerability, stress as an energetic process, ferroptosis imaging, SAM-dependent metabolic vulnerability, and the peptide SS-31 improving aging oocytes.
• New review in Trends in Neurosciences on the mitochondrial epigenome & noncoding genome in aging and brain diseases.
→ https://t.co/lpdwCaCM2x
• Quintana Lab preprint (bioRxiv): Why neurons are especially vulnerable to mitochondrial disease.
→ https://t.co/6FdrxbDdIp
• Super-resolution imaging of stress-modulated mitochondria-lysosome crosstalk in ferroptosis (CCS Chemistry).
→ https://t.co/xClYTnu6Sa
• Picard et al. review (Frontiers in Neuroendocrinology): Mitochondria as active regulators of the psychological stress response (energy, hormones, bidirectionality, depression links).
→ https://t.co/70fqkEaDYn (detailed summary thread)
• Aging Cell 2026 study: SS-31 (elamipretide) improves mitochondrial function and quality of aging oocytes (mouse + human in vitro).
→ https://t.co/yNZ0VB40nn
• Science Advances (Karolinska): SAM depletion causes physical dismantling of the cellular energy grid / lipoylation-dependent vulnerability in the postnatal heart.
→ https://t.co/143pGyKyfj
#Mitochondria #MitoScience #Aging #BrainHealth #Stress #Ferroptosis #MitochondrialDisease
Your body burns more energy responding to psychological stress than it does running a mile. That energy comes from mitochondria, and @MitoPsychoBio Martin Picard argues those ancient organelles don't just power the stress response, they actively shape it.
Picard and colleagues published a landmark review in Frontiers in Neuroendocrinology proposing a fundamentally new way to understand stress: as an energy-driven process centered on mitochondria.
The central premise is simple but profound. Every aspect of your stress response requires energy. Gene expression, hormone synthesis, neurotransmitter release, immune activation, tissue remodeling. None of it happens without ATP, and nearly all cellular ATP comes from mitochondria.
But the relationship goes deeper than mitochondria just providing fuel. The review identifies four interconnected ways mitochondria and stress interact.
First, stress responses increase energy demand across multiple biological levels. At the molecular level, turning genes on and off requires energy. Cells need energy to produce proteins. Tissues need energy to remodel. Your entire organism needs energy to mount behavioral and physiological responses to threats.
Think of it this way: when you perceive a stressor, your brain activates the hypothalamic-pituitary-adrenal axis and sympathetic nervous system. Those cascades trigger widespread changes. Your heart rate increases. Blood gets redirected. Immune cells mobilize. Glucose floods your bloodstream. All of that coordination requires substantial energy investment.
Second, mitochondria don't just consume stress hormones, they produce them. This is counterintuitive because we typically think of hormones coming from glands. But mitochondria synthesize and metabolize both glucocorticoids like cortisol and catecholamines like adrenaline.
The enzymes that convert cholesterol into cortisol are located in mitochondria. The same goes for the breakdown pathways. This means mitochondria actively participate in setting the hormonal tone of your stress response, not just responding to it.
Third, the relationship is bidirectional. Stress hormones alter mitochondrial function. Glucocorticoids can enhance mitochondrial energy production in some contexts while impairing it in others, depending on dose, duration, and tissue type.
Acute stress exposure tends to boost mitochondrial capacity, preparing cells for increased energy demand. Chronic stress does the opposite, progressively degrading mitochondrial function and reducing cellular energy capacity. This creates a vicious cycle where impaired mitochondria can't support adequate stress responses.
Fourth, and perhaps most compelling, experimentally manipulating mitochondrial function changes how organisms respond to psychological stress. Picard cites studies where researchers altered mitochondrial DNA or respiratory chain function in mice and observed completely different stress response patterns.
Mice with mitochondrial defects show altered glucocorticoid responses, different behavioral reactions to stressors, and distinct patterns of social behavior. This demonstrates mitochondria aren't passive energy suppliers, they actively regulate stress physiology.
The review also connects mitochondrial function to depression and other stress-related disorders. Depression involves metabolic dysregulation. People with depression often show altered glucose metabolism, insulin resistance, and changes in appetite and energy-seeking behavior.
These metabolic changes may reflect underlying mitochondrial dysfunction. When cellular energy production falters, the brain's capacity to maintain normal mood regulation and stress adaptation declines. The fatigue, cognitive slowing, and motivational deficits characteristic of depression may partly stem from inadequate energy supply to neural circuits.
Picard introduces the concept of mitokines, signaling molecules produced by mitochondria that influence physiology beyond the cell. These include reactive oxygen species, metabolites, peptides, and even mitochondrial DNA fragments that escape into the cytoplasm or bloodstream.
Mitokines can trigger inflammatory responses, alter gene expression in distant tissues, and influence whole-organism metabolism. They represent a signaling channel through which mitochondria communicate cellular energy status to the rest of the body.
Key points from the review:
• Energy flow, not just molecular composition, distinguishes living organisms from dead ones
• Mitochondria are endocrine organelles that both produce and respond to stress hormones
• Acute stress enhances mitochondrial function while chronic stress degrades it
• Mitochondrial defects alter stress reactivity, social behavior, and mental health
• Depression and metabolic disease may share mitochondrial dysfunction as a common mechanism
• Mitokines allow mitochondria to signal energy status across cells and tissues
• Sexual dimorphism in mitochondrial function may explain sex differences in stress responses
The paper also addresses sex differences. Females generally have higher mitochondrial content and better mitochondrial function than males in many tissues. This may contribute to sex-specific patterns in stress-related disorders, with women showing higher rates of depression and anxiety while men show higher rates of metabolic syndrome.
The implications reframe how we think about stress adaptation and pathology. If stress is fundamentally an energetic process, interventions that support mitochondrial health, exercise, adequate sleep, nutritional sufficiency, might protect against stress-related disease not just through psychological mechanisms but through direct effects on cellular energy capacity.
The framework also suggests new therapeutic targets. Rather than only modulating neurotransmitter systems or hormone levels, treatments might aim to restore mitochondrial function and energy metabolism in stress-responsive tissues.
This is one of the most important conceptual papers in stress biology. Picard makes the case that we can't fully understand psychological stress without understanding cellular energetics, and we can't understand cellular energetics without centering mitochondria.
The review calls for more research defining how mitochondria influence human stress responses across the lifespan. Most mechanistic work comes from animal models. Translating these insights into clinical applications requires better tools to measure mitochondrial function in humans and interventional studies testing whether improving mitochondrial health protects against stress pathology.
Stress isn't just neurochemical or hormonal. It's energetic. And the organelles managing that energy don't just keep the lights on, they help determine whether stress makes you stronger or breaks you down.
Research from Karolinska Inst. shows that low levels of the molecule SAM inside mitochondria disrupt energy production. When mitochondrial SAM drops, complex I becomes unstable and iron-sulfur cluster biosynthesis fails, impairing the respiratory chain.
This links one-carbon metabolism directly to mitochondrial function, with implications for aging and disease.
https://t.co/6iANkFqLX0
#health #Mitochondria #Inflammaging
Drilling down to the source of the problems:
Viruses Trigger Hyper-Glycolysis
Viruses are non-living intracellular parasites that need massive amounts of molecular "parts" to replicate quickly.
Rapid Building Blocks. Diverting glucose away from the mitochondria feeds side pathways like the pentose phosphate pathway (PPP). This rapidly generates nucleotides for viral DNA or RNA, amino acids for viral proteins, and lipids for viral envelopes.
Fast Energy Production. Although glycolysis produces far less ATP per glucose molecule than mitochondrial respiration (2 ATP vs. up to 36 ATP), it operates 10 to 100 times faster. This provides immediate bursts of energy for viral assembly.
Transporter Upregulation. Viruses activate host signaling pathways (such as HIF-1α and mTOR) to flood the cell surface with glucose transporters like GLUT1 and GLUT3, pulling in excess fuel.
How This Shift Affects Mitochondria
Because hyper-glycolysis reroutes cellular fuel and alters the internal chemical environment, mitochondria undergo severe structural and functional stress.
Suppression of Oxidative Phosphorylation (OXPHOS). Because pyruvate is converted into lactate in the cytoplasm rather than entering the mitochondria, normal mitochondrial respiration drops sharply. To survive, mitochondria are often forced to switch to alternative fuels like glutamine or fatty acids to keep the tricarboxylic acid (TCA) cycle running for biosynthetic precursors.
Disruption of Antiviral Immune Signaling (MAVS). Mitochondria serve as critical alarm hubs for the immune system via the Mitochondrial Antiviral-Signaling (MAVS) protein on their outer membranes. The excess lactate produced by hyper-glycolysis directly binds to MAVS, physically blocking it from triggering type I interferon responses. This allows the virus to replicate undetected.
Oxidative Stress and ROS Damage. Direct viral protein interactions and metabolic bottlenecks cause electrons to leak from the mitochondrial electron transport chain. This generates high levels of reactive oxygen species (ROS), which damage mitochondrial DNA (mtDNA) and membranes.
Altered Mitochondrial Dynamics (Fission and Fusion). Healthy mitochondria constantly merge (fusion) and divide (fission) to maintain efficiency. Viral metabolic reprogramming and calcium imbalances frequently trigger excessive fission (fragmentation). Fragmented mitochondria are less efficient at producing energy and are further impaired in their ability to coordinate immune defenses.
Mitophagy and Cell Fate Manipulation. Depending on the virus's life cycle, it may trigger mitophagy (the selective destruction of damaged mitochondria) to prevent the cell from undergoing premature programmed cell death (apoptosis), keeping the host cell alive as a viral factory. Conversely, once replication is complete, severe mitochondrial depolarization triggers apoptosis to burst the cell and release new viral particles.
One among many of the authoritative sources: https://t.co/u3JIsFqpUd
🧠🔥 What if Alzheimer’s disease spreads not only through amyloid-β and tau—but also through mitochondrial-derived extracellular vesicles carrying a metabolic enzyme?
A new study in Nature Aging identifies microglial GGT1-enriched mitovesicles (mtVs) as a previously underrecognized mechanism connecting mitochondrial dysfunction, glutathione metabolism, neuroinflammation, and Alzheimer’s disease (AD) progression.
The central discovery: Pathological mitochondrial vesicles transmit GGT1-associated dysfunction between brain cells, while suppressing vesicle release or GGT1 activity alleviates AD-like pathology in mice.
🔬 1. Mitovesicles accumulate in Alzheimer’s disease brains
Mitovesicles are a distinct class of extracellular vesicles characterized by:
• Mitochondrial origin
• Double-membrane structures
• Enrichment of mitochondrial proteins
• Smaller average size than conventional exosomes
Researchers separated brain extracellular vesicles into three populations:
• Microvesicles: ANXA1⁺
• Exosomes: CD9⁺/Flotillin1⁺
• Mitovesicles: PDH-E1α⁺/VDAC1⁺
The average particle sizes were approximately:
• Microvesicles: 181 nm
• Exosomes: 162 nm
• Mitovesicles: 142 nm
Cryo-electron microscopy confirmed the characteristic double-membrane structure of mtVs.
Importantly, mitovesicle abundance was significantly increased in:
• 5×FAD Alzheimer’s mice
• Tau PS19 mice
• Aβ oligomer-exposed mouse brains
• Postmortem brains from patients with AD
Human brain samples showed significantly higher PDH-E1α, VDAC1, and mtV particle abundance compared with cognitively normal controls.
These findings suggest that enhanced mtV release accompanies AD-associated mitochondrial dysfunction.
⚡ 2. Alzheimer’s-derived mitovesicles can induce cognitive dysfunction
Researchers isolated mtVs from 6-month-old 5×FAD mice and injected them into the hippocampi of 2-month-old wild-type mice.
One month later, mice receiving AD-derived mtVs exhibited:
• Impaired Morris water maze performance
• Reduced exploration of novel arms in the Y maze
• Increased microglial activation
• Elevated neuroinflammatory signaling
• Reduced synaptic function
• Greater mitochondrial structural damage
Approximately 70% of Iba1⁺ microglia contained labeled mtV particles one hour after injection.
By comparison:
• Astrocytes: <20%
• Neurons: <30%
This identifies microglia as major recipients of experimentally administered brain-derived mtVs.
🧬 3. Pathological mtVs amplify neuroinflammation
Following ADmtV administration, microglia exhibited increased activation markers and inflammatory responses.
Key changes included:
• CD68⁺/Iba1⁺ microglia ↑
• COX2 ↑
• NF-κB ↑
• IL-10 ↓
• ROS accumulation ↑
• Microglial phagocytic capacity ↓
These observations support a model in which mtVs propagate mitochondrial stress and inflammatory signaling through microglial populations.
The resulting inflammatory environment may contribute to synaptic injury and impaired neuronal function.
🔋 4. Mitovesicles accelerate Alzheimer’s pathology
When ADmtVs were administered to young 5×FAD mice, they accelerated the emergence of AD-like pathological changes.
Compared with controls:
• Aβ plaque burden ↑
• Aβ1–42 accumulation ↑
• Disease-associated Clec7A⁺ microglia ↑
• COX2, NF-κB, and IL-1β ↑
• Dendritic spine density ↓
• Synaptic proteins PSD95 and SY38 ↓
• Miniature excitatory postsynaptic current frequency ↓
• Mitochondrial structural damage ↑
Importantly, APP-processing proteins, including PS1, PS2, and BACE1, were not significantly altered.
This suggests that mtVs may exacerbate Aβ accumulation through mechanisms beyond increased amyloid precursor protein processing.
However, altered Aβ clearance was not directly established as the responsible mechanism.
🧪 5. Mitochondrial metabolism regulates mitovesicle release
The researchers investigated how mitochondrial bioenergetics controls mtV production.
They identified several metabolic and trafficking regulators.
Interventions reducing mtV release:
• FHIN1 — fumarate hydratase inhibition
• Dimethyl fumarate (DMF)
• Coenzyme Q10
• Manumycin A
• EXO-1
Interventions increasing mtV release:
• 4-octyl itaconate
• Oligomycin A
• Chloroquine
These results implicate:
TCA-cycle metabolism → Mitochondrial respiratory function → ESCRT-associated trafficking → Mitovesicle release
Interestingly, mitochondrial fission inhibition with Mdivi-1 did not significantly alter mtV abundance under the tested conditions.
The findings suggest that mtV biogenesis is regulated by mitochondrial metabolic state rather than simply mitochondrial fragmentation.
🔥 6. Blocking mitovesicle release improves AD-like pathology
Researchers administered CoQ10 or FHIN1 to 3-month-old 5×FAD mice for 30 days.
Both interventions reduced brain mtV abundance and improved behavioral performance.
Treatment also:
• Reduced Aβ plaque numbers
• Lowered Aβ1–42 levels
• Suppressed Clec7A⁺ microglial activation
• Reduced COX2, NF-κB, and IL-1β
• Restored dendritic spine density
• Increased PSD95 and SY38
• Improved mitochondrial morphology
The protective effects were observed following both systemic administration and direct brain delivery.
However, CoQ10 and FHIN1 influence broader mitochondrial and metabolic pathways.
Therefore, their benefits cannot be attributed exclusively to mtV suppression.
🧬 7. Proteomics identifies GGT1 as a pathogenic mitovesicle cargo
Using quantitative proteomics, researchers identified 4,237 proteins in the analyzed samples.
GGT1 emerged among the most enriched proteins in AD-derived mtVs.
GGT1 is a γ-glutamyltransferase involved in glutathione metabolism.
Its enzymatic activity hydrolyzes glutathione (GSH), influencing cellular redox homeostasis.
The study found:
• GGT1 enrichment in ADmtVs ↑
• GGT1 expression in AD microglia ↑
• Mitochondria-associated GGT1 ↑
• GGT1 abundance in human AD brain tissue ↑
Notably, GGT1 enrichment was preferentially observed in mtVs rather than conventional microvesicles or exosomes.
Human brain transcriptomic data also supported elevated GGT1 expression:
• Cognitively normal individuals: n=87
• Patients with AD: n=100
These findings identify microglial GGT1 as a candidate mediator of mitochondrial vesicle-associated pathology.
⚙️ 8. GGT1 disrupts glutathione-dependent antioxidant defense
Glutathione is a central component of intracellular antioxidant defense.
Under AD-associated conditions, excessive GGT1 activity was linked to:
GGT1 activity ↑
↓
GSH availability ↓
↓
Oxidative stress and ROS ↑
↓
Mitochondrial membrane potential ↓
↓
Microglial inflammatory signaling ↑
↓
Phagocytic dysfunction and neuronal injury
ADmtV exposure reduced GSH abundance and increased ROS in microglia.
It also impaired mitochondrial respiration and cellular energy metabolism.
These results connect extracellular mitochondrial signaling to intracellular redox imbalance.
💊 9. Microglial Ggt1 knockout alleviates Alzheimer’s pathology
To examine causality, researchers generated microglia-targeted conditional Ggt1 knockout mice on a 5×FAD background.
Ggt1 deletion improved:
• Morris water maze performance
• Y-maze behavior
• Aβ plaque burden
• Neuroinflammatory markers
• Dendritic spine density
• Mitochondrial morphology
Importantly, Ggt1 knockout also:
• Increased brain GSH levels
• Reduced oxidative stress-associated signals
These genetic findings strengthen the evidence that microglial Ggt1 contributes to AD-like pathology.
However, the Cx3cr1-CreERT2 system may also target other CX3CR1-expressing myeloid populations, so absolute microglial specificity requires consideration.
💉 10. Pharmacological GGT inhibition reproduces protective effects
Researchers tested acivicin, a pharmacological GGT inhibitor, in 5×FAD mice.
Following 30 days of treatment:
• Cognitive performance improved
• Aβ plaque accumulation decreased
• Neuroinflammation decreased
• GSH levels increased
• Dendritic spine density improved
• Synaptic electrophysiological function improved
• Mitochondrial damage was attenuated
Acivicin also mitigated pathology induced by experimental ADmtV administration.
In cultured microglia, acivicin reversed ADmtV-associated:
• GSH depletion
• ROS accumulation
• Mitochondrial membrane potential loss
• Inflammatory activation
• Phagocytic impairment
• Bioenergetic dysfunction
These findings provide pharmacological support for the GGT1-associated mechanism.
However, acivicin is not selective for GGT1 and also inhibits other enzymes, including GGT5, GGT7, and ALDH4A1.
A more GGT1-preferential inhibitor, SeBo, supported several cellular findings, but selective and clinically suitable GGT1 inhibitors remain necessary.
🎯 11. A new therapeutic framework for Alzheimer’s disease
The proposed mechanism is:
Mitochondrial metabolic dysfunction
↓
Pathological mitovesicle release ↑
↓
Transfer of GGT1-enriched vesicular cargo
↓
Microglial GSH dysregulation
↓
ROS accumulation + Mitochondrial dysfunction
↓
Neuroinflammation + Impaired phagocytosis
↓
Aβ accumulation + Synaptic damage
↓
Cognitive impairment and AD progression
This model suggests two potential intervention strategies:
Strategy A: Suppress pathological mtV release
Target mitochondrial metabolism or vesicle trafficking to reduce propagation of harmful mitochondrial cargo.
Strategy B: Inhibit GGT1-associated redox dysfunction
Preserve glutathione homeostasis and protect microglial mitochondrial function.
These strategies remain experimental and have not been validated as treatments in humans.
🚨 12. Important translational limitations
Several questions remain unresolved:
• Human tissue evidence was largely observational and involved relatively small directly analyzed cohorts.
• Animal experiments used male mice and did not employ randomized group assignment.
• The complete molecular mechanism of mtV biogenesis remains incompletely defined.
• Other vesicular cargoes, including mitochondrial DNA, RNA, and lipids, may contribute to pathology.
• The precise intracellular delivery and functional localization of vesicle-associated GGT1 require further clarification.
• CoQ10 and metabolic inhibitors have pleiotropic effects.
• Acivicin lacks sufficient target selectivity for direct clinical extrapolation.
• Long-term efficacy, safety, and human cognitive outcomes remain unknown.
Importantly, the study does not establish that conventional CoQ10 supplementation prevents or treats Alzheimer's disease in patients.
💡 Key takeaway
Mitochondrial dysfunction may propagate between brain cells through extracellular vesicles carrying metabolically active pathogenic cargo.
This study identifies GGT1-enriched mitovesicles as a candidate mechanism linking microglial redox dysregulation, neuroinflammation, synaptic injury, and Alzheimer’s disease progression.
The work expands the mitochondrial hypothesis of AD beyond intracellular energy failure toward intercellular transmission of mitochondrial metabolic dysfunction.
Targeting pathological mtV release or GGT1-associated glutathione dysregulation may represent a new direction for neurodegenerative disease therapeutics.
📄 Li Y, Xia X, Sun Y, et al.
Mitochondria-derived extracellular vesicles mediate Alzheimer’s disease pathology through transmitting microglial Ggt1.
Nature Aging (2026).
DOI: https://t.co/dJViqb3p7j
Proteomics dataset: IPX0009206000
Metabolomics dataset: https://t.co/XVVMRakNv6
#AlzheimersDisease #Neurodegeneration #Mitochondria #Mitovesicles #ExtracellularVesicles #Microglia #GGT1 #Glutathione #OxidativeStress #Neuroinflammation #MitochondrialMetabolism #BrainAging #NatureAging #AgingResearch
Your mitochondria can trigger the same inflammatory alarms your immune system uses to fight bacteria. That's because mitochondria are bacteria, or at least they were 1.5 billion years ago.
A Nature Reviews Immunology paper maps the molecular mechanisms of how mitochondria control inflammation, the safeguards that normally prevent false alarms, and what happens when those systems fail.
The core problem: mitochondria are ancient bacteria that your cells absorbed roughly 1.5 billion years ago. They still carry bacterial signatures. Your immune system evolved to recognize bacterial molecules as threats. When mitochondria get damaged and leak their contents, your immune system can't distinguish between a broken mitochondrion and an actual infection.
Mitochondria contain multiple damage-associated molecular patterns, or DAMPs. These are molecules that trigger immune responses when detected outside their normal location:
• Mitochondrial DNA (mtDNA): Unmethylated, circular DNA that resembles bacterial genomes
• Cardiolipin: A phospholipid normally confined to the inner mitochondrial membrane
• N-formyl peptides: Proteins with bacterial-style chemical signatures
• ATP and other metabolites: Energy molecules that signal danger when released
These molecules activate pattern recognition receptors, the sensors your immune system uses to detect threats.
The most studied pathway involves mitochondrial DNA activating a detection system called cGAS-STING. Here's how it works:
When mitochondria become damaged, their outer membrane develops holes. Think of it like a breach in a container. The mitochondrial DNA, which normally stays sealed inside, leaks out into the cytosol, the liquid interior of your cell.
An enzyme called cGAS patrols the cytosol looking for DNA that shouldn't be there. When it finds mitochondrial DNA floating around, it produces a signaling molecule called cGAMP. This molecule activates another protein called STING, which sits on the endoplasmic reticulum, a membrane network inside cells.
STING activation triggers the production of interferons, immune signaling proteins your body normally makes to fight viral infections. Your cell responds to leaked mitochondrial DNA the same way it responds to a virus.
A second pathway involves cardiolipin, a fat molecule that normally stays on the inner membrane of mitochondria. When cardiolipin appears on the outer surface or leaks into the cytosol, it activates the NLRP3 inflammasome. This is a multi-protein assembly that acts like an alarm system. Once activated, it produces inflammatory molecules called cytokines, specifically IL-1β, which trigger inflammation throughout surrounding tissue.
Your cells have multiple safeguards to prevent mitochondria from triggering these inflammatory pathways:
Apoptosis suppresses inflammation. Apoptosis is programmed cell death, a controlled self-destruction process. When a cell commits to dying, it activates enzymes called caspases. These enzymes act like molecular scissors, rapidly cutting up mitochondrial DNA and other inflammatory molecules before they can activate immune sensors. Two key studies demonstrated that strong caspase activation prevents the cGAS-STING pathway from turning on during cell death.
Mitophagy removes damaged mitochondria. Mitophagy is selective autophagy, meaning cellular recycling that targets only mitochondria. When mitochondria lose their electrical charge, called membrane potential, or accumulate too much damage, they get tagged with molecular markers. These tags signal cellular machinery to engulf the damaged mitochondrion inside a double-membrane structure called an autophagosome. The autophagosome fuses with a lysosome, which contains digestive enzymes that break down the damaged mitochondrion completely. This happens before its contents can leak out and trigger inflammation.
Chromatin packaging inhibits cGAS. Your nuclear DNA is wrapped around proteins called histones and packaged into a structure called chromatin. This packaging prevents cGAS from detecting it. Mitochondrial DNA lacks this protective packaging, which makes it a much stronger activator of cGAS when it reaches the cytosol. This difference explains why leaked mitochondrial DNA triggers inflammation while nuclear DNA, even when exposed during normal cell division, generally does not.
The pathological consequences emerge when these safeguards fail or get overwhelmed.
Insufficient mitophagy allows damaged mitochondria to accumulate. Their contents gradually leak into the cytosol, triggering chronic low-grade inflammation. This process contributes to age-related inflammatory diseases, neurodegenerative disorders, and metabolic dysfunction.
Defective apoptosis prevents proper DAMP degradation. Cells that can't complete programmed death release intact mitochondrial components that activate stronger inflammatory responses. This mechanism appears in some autoimmune conditions where defective clearance of dying cells drives chronic inflammation.
Excessive mitochondrial stress overwhelms quality control. When mitochondrial damage happens faster than mitophagy can remove it, cells release mitochondrial DAMPs even with functioning safeguards. This occurs during ischemia-reperfusion injury, severe metabolic stress, and certain infections that specifically target mitochondria.
The inflammation can become bidirectional. Inflammatory signals like TNF-α and interferons feed back to impair mitochondrial function, creating cycles where inflammation damages mitochondria and damaged mitochondria amplify inflammation.
Several human diseases show clear links to dysregulated mitochondria-driven inflammation:
Parkinson's disease involves mitochondrial dysfunction in dopaminergic neurons. Defective mitophagy allows damaged mitochondria to trigger inflammatory responses that accelerate neurodegeneration.
Systemic lupus erythematosus shows elevated mtDNA in circulation and enhanced cGAS-STING activation. Defective clearance of dying cells releases mitochondrial contents that drive autoantibody production.
COVID-19 severity correlates with cGAS-STING pathway activation. Viral infection triggers mitochondrial DNA release, and excessive type I interferon responses contribute to immunopathology.
Cancer cells sometimes exploit insufficient mitochondria-driven inflammation. Tumors with defective inflammatory signaling evade immune surveillance, while therapeutic interventions that trigger controlled mitochondrial DAMP release can enhance anti-tumor immunity.
The therapeutic implications point in two directions.
For inflammatory diseases, blocking mitochondrial DAMP signaling could reduce pathological inflammation. cGAS-STING inhibitors are in development for autoimmune conditions. Enhancing mitophagy might prevent DAMP accumulation before inflammation starts.
For cancer and infections, activating mitochondrial DAMP release could boost immunity. Some chemotherapy drugs work partly by triggering immunogenic cell death that releases mitochondrial DAMPs. Radiation therapy activates similar pathways.
The central insight is that mitochondrial quality control and inflammation are mechanistically linked. The same cellular machinery that maintains energy metabolism also determines inflammatory state. When mitochondria function properly and damaged ones get cleared efficiently, inflammation remains appropriately regulated. When quality control fails, mitochondrial DAMPs drive pathological inflammatory responses.
Your immune system treats broken mitochondria like invading bacteria because, evolutionarily, that's exactly what they once were. The molecular signatures persist. What determines health versus disease is how effectively your cells maintain mitochondrial integrity and clear damaged mitochondria before they trigger inappropriate immune activation.
Researchers just proposed a detailed timeline linking SARS-CoV-2 infection to lasting neurological symptoms — via neuroinflammation and blood-brain barrier compromise.
https://t.co/feuOTatUVH
A Brain Powered by Mitochondria
Every thought, memory and emotion depends on a continuous supply of energy. Although the human brain accounts for roughly 2% of body weight, it consumes about 20% of the body’s resting oxygen. In her presentation, Mitochondria and Brain Energetics, Dr. Nirosha Murugan explores how this energy supply connects cellular biology with learning and subjective experience.
Mitochondria do more than keep neurons alive. Their location within a neuron helps determine where energy becomes available. As described in the presentation, mitochondria occupy distinct compartments within dendrites, the branching structures that receive signals from other neurons. This arrangement supports synaptic plasticity—the ability of connections between neurons to strengthen or weaken as we learn. Memory therefore depends on both communication between cells and the local energy needed to sustain changes in those connections.
Sensing Our Inner Energy State
The presentation introduces metabosception, the proposed ability of the brain to sense and integrate its own metabolic condition. This offers a way to explore how cellular energy availability might contribute to feelings such as fatigue, alertness and motivation.
Murugan also discusses associations between mitochondrial biology and long-term positive or negative psychosocial experiences. These findings suggest a relationship between lived experience and cellular metabolism, although correlations alone cannot establish which changes cause the others. The emerging picture is one of reciprocal influence: experience can affect physiology, while physiological conditions can shape how we experience the world.
The Brain’s Electrical Environment
Brain activity involves chemistry and electricity together. Neurons communicate through neurotransmitters, but their electrical activity also generates local fields that can influence neighbouring cells. This interaction, called ephaptic coupling, adds another layer to communication beyond direct synaptic connections.
From this perspective, the brain can be studied as an analog system whose behaviour depends on continuously changing voltages, chemical concentrations and metabolic conditions. Describing it as an electromagnetic organ highlights a physical feature of neural activity; it does not, by itself, explain consciousness.
Can Patterned Fields Influence Biology?
According to the supplied account of her research, Murugan describes experiments using weak electromagnetic fields patterned after activity associated with long-term potentiation, a process involved in strengthening synapses. These exposures influenced measures of neuronal plasticity and protein expression.
The possibility is intriguing: biological responses may depend on a signal’s timing and pattern as well as its intensity. However, changes observed in experimental neurons do not establish that similar exposures improve human memory or treat mental illness. Proposed explanations involving spin chemistry and radical-pair mechanisms remain subjects of investigation rather than established accounts of brain function.
Energy as a Foundation for Experience
The central idea is that understanding the mind requires attention to its energy supply. Mitochondrial organisation, electrical activity and synaptic change are interconnected parts of the same living system. This perspective broadens the study of memory and mental health by asking how the brain’s metabolic condition supports its ability to adapt, communicate and sustain experience.
Energy does not yet provide a complete explanation of consciousness. It provides an essential foundation for investigating how conscious experience becomes biologically possible.
#Mitochondria #BrainHealth #Bioenergetics #Neuroscience #Memory #Neuroplasticity #BrainEnergy #Consciousness #Metabosception #MentalHealthResearch #NiroshaMurugan #TheGuyFoundation
A major study links six common artificial sweeteners to accelerated brain aging, with the highest consumers experiencing a 62% faster decline in memory and thinking skills.
https://t.co/IxvRXXvgc4